PLAUR and oropharynx cancer: Pre-treatment plasma uPAR was compared to clinicopathological characteristics and showed a significantly higher level in patients with a smoking history of more than 30 pack years (p = 0.006) and in patients with non-oropharyngeal cancers (p = 0.004).